Before the Bell
$
277.72
Change
-1.05 -0.38%
Volume
Volume 446
Dec 20, 2016, 7:08 a.m.
Real time quotes
Previous close
$ 278.77
$ 278.77
Change
-7.63 -2.66%
Day low
Day high
$272.96
$290.51
52 week low
52 week high
$223.02
$333.65
Market cap
$62.31B
Average volume
1.85M
P/E ratio
15.75
Rev. per Employee
$1.47M
EPS
17.69
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on BIIB
-
Biogen shares slip following announcement of new CEO
- Wallace Witkowski
-
Mizuho's Salim Syed says patient with seizure in Biogen study raises 'new potential safety issue'
- Emma Court
-
Biogen Inc. drops 0.3% after day of 5% gains
- Emma Court
-
Biogen surges 5.5% on presentation of Eli Lilly Alzheimer's drug trial results
- Emma Court
-
CORRECTED: Biogen shares rise 1.5% on leak of its Alzheimer's drug data
- Emma Court
-
Biogen shares down 6.6% in premarket trade
- Ciara Linnane
-
10 biotech companies ripe for a buyout, courtesy of Donald Trump
- Michael Brush
-
5 big hurdles to repealing Obamacare
- Michael Brush
-
Biogen shares up 3.9% premarket; Ionis shares up 12.3%
- Ciara Linnane
-
Biogen and Ionis report positive results of Phase 3 trial of treatment for spinal muscular atrophy
- Ciara Linnane
-
Merck’s Alzheimer’s drug data fuel hopes for new treatment
- Ciara Linnane
-
This key Nasdaq gauge is topping out and Apple isn’t helping
- Barbara Kollmeyer
-
Biogen profit beats estimates on sales of MS drug
- MarketWatch.com
- Loading more headlines...
Where does this data come from?
Analyst Estimates »
A data point based on hundreds of brokers buy, sell and hold rating.
Sentiment on BIIB
Analyst Ratings
Other News on BIIB
-
- The Wall Street Journal Interactive Edition
-
Biogen Names Insider New CEO After Five-Month Search, Stock Falls
- Investors Business Daily
-
3 Low-Volatility Biotech Stocks to Buy
- Motley Fool
-
Outlook 2017: This Bull Market Has Legs
- Barrons.com
-
- Seeking Alpha
-
Dupixent Might Help Diversify Regeneron’s Business Model
- MarketRealist.com
-
SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent’s Label
- MarketRealist.com
-
Dupixent Is Being Explored for Multiple Indications in 2016
- MarketRealist.com
-
3 Small-Cap Biotech Stocks on the Rise in 2017
- InvestorPlace.com
-
Moat Investing: Stay Ahead of the Competition
- MarketRealist.com
-
How to Add ‘Moativated’ Stocks to Your Portfolio
- MarketRealist.com
-
My Dashboard Stock Lists: 25% In 1 Year, Part 2
- Seeking Alpha
-
3 Top Biotech Stocks to Buy on Sale
- Motley Fool
-
Trade Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free Profits
- InvestorPlace.com
- Loading more headlines...
Press Releases on BIIB
-
Biogen Names Michel Vounatsos Chief Executive Officer
- BusinessWire - BZX
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com
| Avg. APR | Last Week | 6 Months | |
|---|---|---|---|
| Low Interest | 12.00% | 12.00% | 11.98% |
| Business | 13.16% | 13.16% | 13.12% |
| Student | 13.42% | 13.42% | 13.42% |
| Balance Transfer | 14.44% | 14.41% | 14.38% |
| Airline | 15.15% | 15.15% | 15.08% |
| Reward | 15.27% | 15.25% | 15.29% |
| Cash Back | 15.38% | 15.33% | 15.32% |
| Instant Approval | 17.86% | 17.86% | 18.04% |
| Bad Credit | 22.86% | 22.86% | 22.56% |




